Fig. 2: ARs within 7 d after booster dose. | Nature Medicine

Fig. 2: ARs within 7 d after booster dose.

From: Safety and immunogenicity of SARS-CoV-2 variant mRNA vaccine boosters in healthy adults: an interim analysis

Fig. 2

The percentage of participants who reported local (a) and systemic (b) ARs is shown for 20 participants who received a booster dose of mRNA-1273 (50 µg), 19 participants who received a booster dose of mRNA-1273.351 (20 µg), 19 participants who received a booster dose of mRNA-1273.351 (50 µg) and 20 participants who received a booster dose of mRNA-1273.211 (50 µg). One participant each in the mRNA-1273.351 50-µg and 20-µg groups did not report results for solicited ARs and were excluded from the analysis.

Back to article page